Takeda reports Q1 core EPS 151 yen vs. 176 yen last year

Reports Q1 revenue 1.11B yen vs. 1.21B yen last year. Takeda (TAK) chief financial officer, Milano Furuta, commented: “The impact of VYVANSE generic erosion on Takeda’s FY2025 Q1 results was very significant, but consistent with our expectations, and there is no change to our full-year outlook announced in May. Our late-stage pipeline continues to advance with the announcement in July of positive results from two pivotal Phase 3 studies for oveporexton in narcolepsy type 1, with both studies meeting all primary and secondary endpoints. These results represent a significant scientific milestone, and we are very excited about the potential for our late-stage pipeline to deliver value to the patients we serve and to position Takeda for sustainable growth.”